Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

The Global Cannabis Race Is On.



This article is published in collaboration with Scutify, where you can find real-time markets and stock commentary from Robert Marcin, Cody Willard and others. Download the Scutify iOS App, the Scutify Android App or visit

From the United States to Australia, from Germany to Colombia, the Canadian cannabis sector continues to capitalize on an emerging global industry.

As countries around the world continue to reform their laws and legalize medical marijuana, new opportunities are created for Canadian cannabis producers.

Colombia Cannabis Industry Heats Up

Earlier this week, ICC International Cannabis Corporation (ICC.V) (ICCLF) announced that it has incorporated a subsidiary in Colombia, ICC Colombia S.A.S. to apply for a series of licenses pursuant to Article of the Decree 613 of 2017, Article that develops Law1787 of 2016:

  • Seed License: This license grants a permit for the management of seeds that can be imported, exported, stored, transported and commercialized within Colombia.
  • Non-psychoactive Cannabis Cultivation License: This license grants a permit to grow non-psychoactive cannabis plants, including seeding, purchase and production of seeds, sale, distribution, export and use for scientific purposes.
  • Psychoactive Cannabis Cultivation License: This license grants a permit to grow psychoactive cannabis plants, including seeding, purchase and production of seeds, sale, distribution, export and use for scientific purposes.
  • Manufacturing License: This license grants a permit for the formulation and manipulation of cannabis by-products. These can be imported, exported, stored, transported and marketed.

According to the latest news released by the Colombian Government, regulations are expected to be ready in the second half of 2017. This move is part of ICC's strategy to become the world's largest and lowest cost producers of CBD. The new subsidiary combined with ICC's track record leave the company confident in their opportunity. ICC expects to enter new jurisdictions in the coming months.

Canopy: A Global Growth Opportunity

Canopy Growth Corp. (WEED.TO) (TWMJF) has evolved from being the largest licensed medical cannabis producer in Canada into the largest licensed producer in the world. The company sells cannabis on three continents and it continues to increase its market share by making strategic investments all over the world.

In late 2016, Canopy Growth reported an agreement to acquire MedCann GmbH Pharma and Nutraceuticals, a German-based pharmaceutical distributor that has placed Tweed-branded cannabis strains in German pharmacies. MedCann is federally licensed by the German Health Ministry to import, manufacture and distribute medical cannabis products.

Canopy Growth has also entered the Australian medical cannabis industry through a partnership with AussCann (ACNNF). Canopy will help AussCann increase market share and capitalize on the Australian cannabis market. Canopy is not only one of AussCann's largest shareholders but they have also granted them royalty-free access to their intellectual property as it relates to cultivation, supply, and manufacturing of medicinal cannabis.

Canadian Producer Plants Flag in Florida

In April, Aphria Inc. (APH.TO) (APHQF) announced the launch of its United States expansion strategy through a lead investment in Liberty Health Sciences which will operate under Aphria USA.

Less than two month later, Aphria executed on the first step of its expansion plans. Through a strategic investment into DFMMJ Investment, Aphria entered an exclusive management agreement with Chestnut Hill Tree Farm. Chestnut is a Florida nursery authorized by the Florida Department of Health as a medical cannabis dispensary to patients in Florida. Chestnut holds 1 of 7 Florida licenses with Chestnut Hill Tree Farm.

The Florida medical marijuana industry took an important step forward last week. Although we think the new legislation is still not enough, is a step in the right direction and a long-term catalyst for Aphria.

Become a Technical420 Premium Member to learn more!

Important Investor Disclosures

This content was authored by and is property of Technical420. All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report. Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice. Any projections or other information generated by Technical420 regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results. None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment. This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation. The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals. It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction. Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks. The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission. Please contact a Financial Advisor for professional advice regarding any and all securities investments. This report is intended for informational purposes only StoneBridge Partners's officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners. StoneBridge Partners may receive compensation from the company and/or has a position in the securities mentioned in this report.

This article was written by Mark Maulden for on .

This article published in collaboration with Scutify, the best app for traders and investors. Download the Scutify iOS App, the Scutify Android App or visit

< Previous
  • 1
Next >
Featured Videos